Search clinical trials for: SEP-363856 100mg

Total 4122 results

Sumitomo Pharma America, Inc.

Completed

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Croatia, Bulgaria, Latvia, Russian Federation, Ukraine
Phloronol Inc.
Worldwide Clinical Trials

Completed

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Safety Issues

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
Inmagene LLC

Recruiting

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
Sumitomo Pharma America, Inc.

Completed

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Colombia, Bulgaria, Russian Federation, Ukraine
Sunovion

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (SEP-363856)

Schizophrenia

United States
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Schizophrenia

Japan
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Schizophrenia

United States, Serbia, Ukraine, Croatia, Colombia, Russian Federation, Bulgaria, Latvia
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Schizophrenia

Japan
Sunovion

Completed

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Schizophrenia

United States, Ukraine, Russian Federation, Hungary, Romania
Ensol Bioscience

Completed

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

Healthy

Korea, Republic of
Sumitomo Pharma America, Inc.

Completed

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Schizophrenia

Japan
Sunovion

Completed

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Recruiting

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States, Spain, Japan, Bulgaria, Estonia, Finland, Slovakia, Sweden
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Schizophrenia

Hungary, United States, Romania, Ukraine, Russian Federation
Sunovion

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

United States
Dong Wha Pharmaceutical Co. Ltd.

Completed

To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Korea, Republic of
Medicines for Malaria Venture

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

Healthy Volunteers | Malaria Falciparum | Malaria Vivax

United States
MyMD Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

Frailty | Sarcopenia | Aging

United States
Vigonvita Life Sciences

Completed

Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

Healthy Subjects

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Sudapyridine (WX-081) in Healthy Volunteers

Healthy

China
Otsuka Pharmaceutical Development & Commercialization...
Sumitomo Pharma Co., Ltd.; Sumitomo Pharma America, Inc.

Recruiting

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
Bio-Thera Solutions

Completed

A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients

Non-Hodgkin's Lymphoma

China
Genzyme, a Sanofi Company

Completed

ZD6474 Phase IIa Dose Finding Multicentre Study

Non Small Cell Lung Carcinoma

Japan
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Acute Myeloid Leukemia

China
NeuroBo Pharmaceuticals Inc.
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy

United States
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathic Pain

Diabetic Neuropathies

Korea, Republic of
Sumitomo Pharma America, Inc.

Active, not recruiting

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Enrolling by invitation

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Schizophrenia

United States
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Netherlands
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Schizophrenia

United States
Sunovion

Completed

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

Schizophrenia

United Kingdom
GlaxoSmithKline

Completed

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

Hepatitis C

United States
KGK Science Inc.
ChromaDex, Inc.

Completed

A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects (14NBHC)

Pharmacokinetics

Canada
Sunovion

Completed

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

Schizophrenia

United States
Dong Wha Pharmaceutical Co. Ltd.

Completed

Pharmacokinetic Profiles of Metformin With DW1029M (PMD)

Healthy

Korea, Republic of
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
The First Hospital of Jilin University

Recruiting

Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (MB07133)

Efficacy | Safety Issues | MTD

China
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Pregnancy | HIV-1-infection | Postpartum

United States, South Africa
Yuhan Corporation

Completed

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of

3

Subscribe